Chromosome analysis showed a ring chronioson~e 5 in 88Stof the cells, a double ring in 2% and two rings in I%, while in 9% the rtng was lost. No delectiotls were found. The sister's and parent's cliromosonies were normal. This i s the first case of ring chromosome 5 associaled with a stimulated partial CH deficiency.
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SHORT TERM METABOLIC CHANGES AND LONG TERM RESPONSE TO RECOMBINANT IGF-I (rhIGF-I) THERAPY IN A NORTH AMERICAN CHILD WITH GH INSENSITIVITY (GHIS; LARON SYNDROME).
P.M. Martha, Jr., C. Johnston, P. Cohen, R. Rosenfeld and E.O. Reiter, Depts of Peds, Baystate Med Center, Springfield, MA and Stanford Univ, Stanford, CA, USA.
We report results of the first 9 mos of ~~I G F -I RX in a 10.6 y o Caucasian girl with apparently sporadic GHIS.
She was born in the USA into a family with no significant short stature.
Dx of GHIS was based on: growth failure (HT SDS=-6.2; GV=3.6cm/y over 8.5 yrs), delayed BA (-4.5 SDS), elevated GI1 (baseline values 27-42 ng/ml; peak to stimuli 94-192), low IGF-I and IGFBP-3, very low GHBP, and no lncrease in IGF-I or growth velocity during 2 courses of GH Rx. In the first 11 days of Rx, the rhIGF-I (Kabi Pharmacia, Stockholm) dose was increased from 40 to 120 ug/kg bid. Urinary Ca excretion increased >2-fold, Cr clearance rose 718, fasting insulin declined in a dose-dependent manner, IGF-11 fell from 93 to 53 ng/ml while first morning IGF-I levels remained low (<18ng/ml). During 9 mos of IGF-I Rx (120 ug/kg bid), GV rose strikingly to 10.2 cm/yr resulting in an improvement in predicted adult ht of 7.2 cm. Increased Ca excretion and Cr clearance were maintained.
No significant hypoglycemia has occurred. In conclusion, rhIGF-I has been a safe and effective growth-promoting agent in a girl with sporadic GHIS. The specific gene defect In this child is unknown.
GROWTH HORMONE T H E
University of South Carolina, Charleston SC 29425, USA Growth hormone may be involved in normal cartilaqe production. Two patients with GH deficient states were treated with GH. Both patients, one with panhvpopitultarlsrn (patlent 1) and another wlth pseudohypop~r~thy-roldlsm (patlent 2) prcscnred wlth severe trochcomalacla. Both patients required tracheostomy. Patient 1 had his tracheostomy at age 3 years and 9 years later, despite numerous ENT procedures to reduce granulation tissue, could not be extubated due to collapse of the tracheal cartilaqe. Patient 1 was treated for hv~othvroidism and
hypoadrenalism. An insulin-glucagon test ;bowed no GH values qreater than 2 nq/ml (Hvbritech IRMA).
At one month oi life, patient -2 had -a trachcostoiy and was diagnosed with pseudohypoparathyroidism with no significant rise in phosphate excretion, cyclic-AMP, or calcium (urinary or serum ionized) after PTH administration. This patient had a low IGF-1 and IBP-3. Patient 1 was treated with GH at a dose of 0.05 mg/kg/dose SC 6X per week; patient 2 at a dose of 0.1 mg/kg/day SC (the higher dose due to resistance to peptide hormones), each for six months.
After treatment, the tracheal cartilage had become more firm, allowing extubation in both patients. This experience suggests a role for GH in the development of tracheal cartilage. 3) 28.9(8.2) 22.5(7.0) 5027(1050) 179(12) Tha mem change i n FFM i n PWS was significantly greater than i n GHD subjects (14.4 v. 6.9s.. p<0.01) One subject (14.2 yr.. weight 78.2kg, BM1 33.9) developed dlabelcs rnell~tus after 3 wks of therapy @re-treatment glywsylaled haemoglobin 7.2%). Following 6 weeks of rhGH treatment. PWS children show a greater change i n FFM lhan children wilh short suture. Growth honnone therapy may be appropriate for long term use i n PWS as a means of incrwing FFM with possible beneficla1 syuelae. However, st should be recognised that there is same risk of diabetes occurring. To combine a classical test for GH secretion with the assessment of GH pituitary reserve, we evaluated GH secretion in short children by two sequential Arginine(Arg1 tests: a first Arg test(Arginine HCL.O.5 g/kq.infused in 30 min),tmmediately followed by a combined ArqtGHRH test (1 og/kg iv bolus of GHRH-(1-24). Peak GH responses were constdered normal when 27 ng/ml after Arg test and >20 ng/ml after ArgtCHRH test. Subjects were 103 children (aged-6-16 years;63 males;)? prepubertal; height (5th centile); 41 wlth normal qrowth rate (height velocity SD score >-0.80); 26 with borderline growth rate (HVSDS -0.80 to-2); 35 with slow growth rate (HVSDS ( -2 ) . Results. a) Normal responses to both tests were found in 79 (76.71) subjects (33.22.24. in normal. borderline and slow growth groups, respectively); low responses to Arg but normal to ArqtGRRH were found In 22 (21.41) children (8.3,11 in normal, borderline and slow qrowth groups.respective1y); low responses to both test were found in 2 subjects, with borderline and slow growth. bJ In 72 children, a Clonidine test(0.15 mg/m';normal peak >7 ng/ml) showed a 73.32 concordance wlth the Arg test. c) In 20 children, mean overnight GH secretion was evaluated (UGHC) and a score was assigned to both GH peaks after ArgtGHRH test: a combined score > 10 predicted 911 of UGHC greater than 3 ng/ml. In conclusion, the sequential Arginine-Arginine plus GHRH test ia a safe and convenient procedure for an initlal characterization of S49 GH secretion and GH pltultary reserve in short children.
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ARGININE INFUSION FOLLOWED BY ARGININE PLUS GROWTH HORIIONE(GH)
RELEASING
